Table 3.

LABA + LAMA combinations currently available or in development

LABA + LAMA combinationsa	Company
Available
Aclidinium/formoterol	AstraZeneca (London, UK)
Glycopyrronium/indacaterol	Novartis (Basel, Switzerland)
Tiotropium/olodaterol	Boehringer Ingelheim (Ingelheim, Germany)
Umeclidinium/vilanterol	GlaxoSmithKline (London, UK)
In development
Glycopyrronium/formoterol	AstraZeneca (London, UK)

Note:

^aIn alphabetical order.

Abbreviations: LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist.